KEI Comments to NIH on Exclusive License to Neurala
On June 2, 2025, KEI submitted comments regarding Neurala Bio being granted an exclusive license by the NIH for “c-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same” (90 FR 21054). KEI’s primary concern as… Continue Reading